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Bulleted Statements: 
What’s already known about this topic? : 
 Autoantibodies to melanoma differentiation-associated protein 5 (MDA5) are 
associated with a subset of patients with dermatomyositis (DM) accompanied by 
rapidly progressive interstitial lung disease with poor prognosis. 
 In anti-MDA5 antibody-associated DM patients, serum levels of ferritin and anti-
MDA5 antibodies correlate with the disease activity. 
 
 
What does the study add? :  
 This study reveals that intravenous immunoglobulin (IVIG) contributes to control of 
the disease activity of anti-MDA5 antibody-associated DM. 
 Combined modality therapy including IVIG is recommended for treatment of anti-
MDA5 antibody-associated DM. 
 Palmar violaceous macules/papules around the interphalangeal joints might be a 
useful sign to suggest a diagnosis of anti-MDA5 antibody-associated DM.  
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ABSTRACT  
Autoantibodies to melanoma differentiation-associated protein 5 (MDA5) are associated 
with a subset of dermatomyositis (DM) patients who have rapidly progressive interstitial 
lung disease (RP-ILD) with poor prognosis. Intensive immunosuppressive therapy is 
initiated before irreversible lung damage can occur; however, there are few lines of 
evidence for the treatment of RP-ILD. Here, we report 3 cases of anti-MDA5 antibody-
associated DM with RP-ILD in which the patients were treated with combined modality 
therapy including high-dose prednisolone, tacrolimus, intravenous cyclophosphamide, 
and immunoglobulins (IVIG). In all 3 cases, the serum ferritin levels, which are known 
to represent the disease activity of RP-ILD, were decreased after IVIG administration. 
IVIG might contribute to control of the disease activity of anti-MDA5 antibody-positive 
DM. Moreover, palmar violaceous macules/papules around the interphalangeal joints, 
which was observed in all 3 cases in the incipient stage, might be a useful sign to suggest 
a diagnosis of anti-MDA5 antibody-associated DM. 
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Autoantibodies to melanoma differentiation-associated protein5 (MDA5) are 
associated with a subset of clinically amyopathic dermatomyositis (DM) patients with 
rapidly progressive interstitial lung disease (RP-ILD) with poor prognosis1,2. Moreover, 
levels of serum ferritin and anti-MDA5 antibody were associated with the status of ILD2-
4. In anti-MDA5 antibody-positive patients, intensive immunosuppressive therapy is 
initiated before irreversible lung damage can occur; however, there are not many lines of 
evidence for the treatment of RP-ILD. Here, we report 3 cases of anti-MDA5 antibody-
associated DM with RP-ILD in which the patients were treated with combined modality 
therapies including intravenous immunoglobulins (IVIG), which probably contributed to 
control of the disease activity. 
 
Case report 
Case 1 
A 57-year-old woman presented with a 1-month history of periorbital edematous 
erythema (heliotrope rash), palmar violaceous macules/papules around the 
interphalangeal joints (Fig. 1a), scaly erythema over the dorsum of the 
metacarpophalangeal, interphalangeal, cubital, and knee joints and the auricles (Gottron’s 
papules and Gottron’s signs), and nail-fold telangiectasia. Biopsy from the Gottron’s 
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papules around the interphalangeal joints showed basal cell vacuolar degeneration, mild 
perivascular lymphocytic infiltrate (interface dermatitis), and mucin deposition in the 
dermis. Manual muscle testing (MMT) revealed slight weakness of the flexor muscles of 
the neck. The laboratory data indicated slightly elevated serum levels of ferritin, lactate 
dehydrogenase (LDH), creatine kinase (CK), aldolase, aspartate amino-transferase (AST), 
and alanine transaminase (ALT), and normal serum levels of Krebs von den Lungen-6 
(KL-6) and surfactant protein D (SP-D) (Table 1). Anti-MDA5 antibody was positive 
(197.6 index value, yielded by enzyme-linked immunosorbent assay [ELISA]). 
Computed tomography (CT) of the chest showed ground-glass opacities in the right 
inferior lobe of the lung (Fig. 2a). DM was diagnosed, and the patient was given oral 
prednisolone at 1.0 mg/kg/day with oral tacrolimus and biweekly intravenous 
cyclophosphamide (IVCY) at 500 mg/m2. The eruptions were gradually disappeared. 
However, the serum ferritin level rapidly increased without any symptoms; thus, monthly 
IVIG (400 mg/kg/day for 5 days) was administered (Fig. 3a). Because both the serum 
ferritin level and the anti-MDA5 antibody index value rapidly decreased and because CT 
showed no further progression of ILD (Fig. 2a) with the slightly reduced serum KL-6 
levels to 392 IU/mL, the oral prednisolone dose was gradually tapered and IVCY was 
stopped after 7 courses (Fig. 3a). 
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Case 2 
A 57-year-old woman had been hospitalized in the neurology department of our hospital 
because of worsen paresthesia in the lower extremities from a month before. She 
developed edematous erythema over the left upper eyelid (heliotrope rash), Gottron’s 
papules over the metacarpophalangeal and interphalangeal joints, palmar violaceous 
macules/papules around the interphalangeal joints (Fig. 1b), and scaly and itchy erythema 
on the precordium and the shoulders. As in case 1, biopsies from the Gottron’s papules 
and palmar violaceous macules/papules showed interface dermatitis with mucin 
deposition in the dermis. MMT revealed slight weakness of the left hamstrings. The 
laboratory examinations indicated slightly elevated serum levels of ferritin, LDH, and 
AST and normal serum levels of KL-6, SP-D, CK, aldolase, and ALT (Table 1). Anti-
MDA5 antibody was positive (200.3 index value, yielded by ELISA). CT showed ground-
glass opacities in the right inferior lobe of the lung (Fig. 2b). DM was diagnosed, and the 
patient was given oral prednisolone 1.0 mg/kg/day with oral tacrolimus and biweekly 
intravenous cyclophosphamide (IVCY) at 500 mg/m2. One week after administration of 
the combined therapy, the serum ferritin level increased rapidly, as did the anti-MDA5 
antibody index value; thus, IVIG (400 mg/kg/day for 5 days) was added. In this case, after 
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only 1 course of IVIG, the serum ferritin level decreased (Fig. 3b). Accordingly, the ILD 
and eruptions gradually improved with the slightly reduced serum KL-6 levels to 191 
IU/mL (Fig. 2b), the dose of oral prednisolone was tapered and IVCY was stopped after 
4 courses (Fig. 3b).  
 
Case 3 
A 66-year-old man presented with edematous erythema over the right upper eyelid 
(heliotrope rash), scaly erythema on the metacarpophalangeal, interphalangeal, and 
cubital joints (Gottron’s signs), palmar violaceous macules/papules around the 
interphalangeal joints (Fig. 1c), and nail-fold telangiectasia, with complaints about neck 
and shoulder pain gradually worsening from 1 month before. Biopsies from the heliotrope 
rash, Gottron’s signs, and palmar violaceous macules/papules revealed interface 
dermatitis. MMT indicated slight weakness of the bilateral deltoid and biceps brachii 
muscles. The laboratory examinations indicated elevated serum levels of ferritin, LDH, 
CK, AST, and ALT, and normal serum levels of KL-6, SP-D, and aldolase (Table 1). 
Anti-MDA5 antibody was positive (213.5 index value, yielded by ELISA). CT showed 
ground-glass opacities and reticular shadows in the inferior lobes of both lungs (Fig. 2c). 
DM diagnosed, and the patient was given high-dose oral prednisolone (1 mg/kg), 
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tacrolimus at 5 mg/day, IVIG (400 mg/kg/day for 5 days), and IVCY at 750 mg/cm2 (Fig. 
3c). The eruptions gradually improved after the therapies. Because RP-ILD occurred (Fig. 
2c) with a rapidly increased serum level of ferritin, we added methylprednisolone pulse 
therapy (1000 mg/day for 3 days). Although the serum ferritin level dramatically 
decreased (from over 8000 to less than 2000 ng/mL), as did the anti-MDA5-antibody 
index value, after the combined modality therapy (Fig. 3c), the patient died of respiratory 
failure with severe RP-ILD a month after we started treatment. In contrast to the reduced 
serum levels of ferritin and the anti-MDA5-antibody index value, the serum KL-6 level 
remained to be elevated (from 455 to 1640 U/mL) during the clinical course in this case. 
 
Discussion 
 A meta-analysis study estimated that the pooled sensitivity and specificity of 
anti-MDA5 antibodies for RP-ILD were 77% and 86%, and the pooled diagnostic odds 
ratio was 20.415. Gono et al reported that the cumulative 100-month survival rate for the 
entire anti-MDA5 antibody-positive DM patient group was 66% and a fatal outcome 
occurred remarkably often within the first 6 months2. A few previous reports suggested 
that intensive immunosuppressive therapies may improve the survival of RP-ILD in anti-
MDA5 antibody-associated DM patients6,7. It was reported that treatment with IVCY 
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(combined immunosuppressive therapy including biweekly IVCY) more than 6 times was 
effectual for patients with DM accompanied by RP-ILD7. Unlike other therapies for DM, 
IVIG is not immunosuppressive and has been used in DM patients for more than 30 years8. 
In all of our 3 cases, treatment with IVIG was used in the incipient stage of the disease, 
which led to dramatically decreased serum ferritin levels and gradually decreased anti-
MDA5 antibody titers. Especially in case 1, the serum ferritin level was decreased 
sensitively with usage of IVIG (Fig. 3a). In case 3, the serum ferritin level was 
dramatically decreased after administration of IVIG and additional steroid pulse therapy 
even though the outcome was fatal; thus, IVIG might also have contributed to temporary 
stabilization of the disease activity.           
 The results of the cases reported here suggest that combined modality therapy 
including IVIG in the incipient stage of the disease, before irreversible lung damage 
develops, might improve the survival of anti-MDA5 antibody-associated DM patients 
with RP-ILD. Fiorentino D et al. demonstrated that patients with DM presenting with 
cutaneous ulcerations and/or palmar papules may not have characteristic muscle 
inflammation of DM but are at increased risk of subacute or rapidly progressive interstitial 
lung disease9. Because palmar papules were present, we promptly confirmed the 
positivity of anti-MDA5 antibodies by ELISA, which has been established recently6 and 
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is now available in Japan, and subsequently started a combined modality therapy in each 
of the cases. The patients presented with palmar macules/papules that looked violaceous 
uniquely compared to Gottron’s papules/signs. The palmar violaceous macules/papules 
represented not only lichenoid reactions but also bleeding histologically, and were 
developing around the interphalangeal joints, which are protuberant and likely subject to 
pressure. Careful examination of the cutaneous manifestations and quick detection 
systems for the antibody are important to improve the survival rate of anti-MDA5 
antibody-associated DM. 
We have here reported 3 cases of anti-MDA5 antibody-associated DM 
accompanied by RP-ILD treated with combined modality therapy including IVIG started 
in the incipient stage of the disease. In all of the cases, the IVIG therapy probably 
contributed to decrease in the serum level of ferritin, which is known to represent the 
disease activity of anti-MDA5 antibody-associated RP-ILD. Although further evidence 
is needed to establish suitable therapies for anti-MDA5 antibody-associated DM, 
combined modality therapy including IVIG could be the best treatment measure at the 
present time. 
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FIGURE LEGENDS 
Figure 1. Palmar violaceous macules/papules around the interphalangeal joints of case 
1 (a), case 2 (b) and case 3 (c). 
Figure 2. Ground-glass opacities and reticular shadows detected by computed 
tomography (CT). (a) In case 1, ground-glass opacities in the right inferior lobe of the 
lung were detected at the first visit, and had disappeared 74 days after hospitalization. 
(b) In case 2, ground-glass opacities in the right inferior lobe of the lung were detected 
at the first visit, and had almost disappeared 43 days after hospitalization. (c) In case 3, 
ground-glass opacities and reticular shadows in the inferior lobes of both lungs were 
detected at the first visit, and had rapidly progressed 28 days after hospitalization.  
Figure 3. Clinical courses of case 1 (a), case 2 (b) and case 3 (c). IVIG, intravenous 
immunoglobulin; IVCY, intravenous cyclophosphamide. 
 
 



Table 1. Laboratory examinations of the patients at the first visit 
Investigation 
 (normal range) 
Case 1 Case 2 Case 3 
Anti-MDA5 antibody (<32 index value) 197.6 200.3 213.5 
ANA (negative) 
1:40 (homogenous and 
speckled pattern) 
Negative Negative 
Ferritin (3.6 - 114 ng/mL) 482.0 331.1 717.5 
LDH (106 - 211 U/L) 327 337 682 
KL-6 (0 - 499 U/mL) 430 254 455 
SP-D (0-109 ng/mL) 27.1 17.9 36.3 
CK (42 - 150 U/L) 308 124 1169 
Aldolase (2.7 - 5.9 IU/L) 7.1 5.9 4.3 
AST (8 - 38 U/L) 84 49 88 
ALT (4 - 44 U/L) 57 35 159 
MDA5, melanoma differentiation-associated protein 5; LDH, lactate dehydrogenase; KL-6, Krebs von den Lungen-6; SP-D, surfactant 
protein D; CK, creatine kinase; AST, aspartate amino-transferase; ALT, alanine transaminase; ANA, anti-nuclear antibody. 
